Company: TELO
Filing Date: 2025-07-23
Form Type: 8-K
Source: 0001641172-25-020687
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-07-23
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Pharmaceuticals Reports Telomir-1 Demonstrates a Rare Mitochondrial Activity Profile by Selectively Restoring Energy and Improving Oxidative
Balance in Diseased Human Cell Lines Without Causing Them to Divide

Telomir
Pharmaceuticals, Inc. (NASDAQ: TELO) today reported new preclinical results showing that its lead compound, Telomir-1, restored mitochondrial
function without triggering oxidative stress or cell proliferation in human cells derived from a patient with Hutchinson-Gilford Progeria
Syndrome (HGPS).

The
study was conducted in collaboration with Smart Assays Biotechnologies Ltd., a preclinical contract research organization specializing
in advanced cell-based models and drug mechanism profiling. Researchers used a Progeria human fibroblast cell line to evaluate Telomir-1’s
effects on mitochondrial energy production, oxidative balance, and cell replication.

Telomir-1
demonstrated a rare mitochondrial activity profile by selectively increasing mitochondrial energy production while simultaneously reducing
reactive oxygen species (ROS) - a damaging byproduct of oxidative metabolism. Notably, this restoration occurred without causing
the cells to divide, a key safety consideration in genetically unstable or disease-compromised cells.

This
combination - enhanced mitochondrial function, reduced oxidative stress, and no induced proliferation

Key
findings from the study include:

  Increased                                                                                
  mitochondrial energy production, as measured by WST-1 assay, indicating improved energy  
  metabolism in compromised cells                                                          
 ───────────────────────────────────────────────────────────────────────────────────────────
  Reduced                                                                                  
  No                                                                                       
  Stronger                                                                                 

The
observed profile may be relevant to other diseases where mitochondrial failure, oxidative stress, and limited regenerative capacity contribute
to progression, including Parkinson’s disease, ALS (Amyotrophic Lateral Sclerosis), Alzheimer’s disease, Werner’s
syndrome, and Progeria

Telomir
is completing IND-enabling studies for Telomir-1 and continues to evaluate multiple clinical development paths based on scientific rationale,
unmet need, and regulatory strategy.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                     TELOMIR                                       
  Dated:             By:                        /s/                
                     Name:                      E